NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
4 hedge funds and large institutions have $110K invested in NRX Pharmaceuticals Warrant in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
20% less funds holding
Funds holding: 5 → 4 (-1)
77% less capital invested
Capital invested by funds: $486K → $110K (-$376K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$39.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$255K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$9.49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $54K | +$39.5K | +12,480 | +74% |
|
|
YCM
2
Yakira Capital Management
Westport,
Connecticut
| $48K | -$9.49K | -3,000 | -10% |
|
|
3
UBS Group
Zurich,
Switzerland
| $8K | +$6.28K | +1,985 | +84% |
|
|
AA
4
AQR Arbitrage
Greenwich,
Connecticut
| – | -$255K | -54,256 | Closed |
|
NRXPW Hedge Fund Activity: Q4 2021 in Review
4 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q4 2021, worth a combined $110K — down 77% from $486K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NRXPW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $39.5K. The largest seller was AQR Arbitrage, exiting entirely with an estimated $255K sold.
- 4 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q4 2021, down from 5 in Q3 2021.
- Funds reported $110K of NRX Pharmaceuticals Warrant stock for Q4 2021, down 77% quarter-over-quarter.
- 0 funds opened new NRX Pharmaceuticals Warrant positions in Q4 2021 and 1 closed out, a net change of -1 holder.
- The largest NRX Pharmaceuticals Warrant buyer in Q4 2021 was Cambridge Investment Research Advisors, an estimated $39.5K added.
- The largest NRX Pharmaceuticals Warrant seller in Q4 2021 was AQR Arbitrage, an estimated $255K sold.
Based on aggregated 13F filings for Q4 2021.